In subsequent versions of the NCCN guidelines, the panel of molecular tests was expanded to include BRAF, ROS-1, RET, ERBB2 (HER2), KRAS, and MET mutations as routine for patients with lung adenocarcinoma [12]. Here, KRAS is linked to lung adenocarcinoma.